Destiny and Sebela Team Up Over C. Difficile Candidate

Destiny Pharma and Sebela Pharmaceuticals have inked a collaboration and co-development deal over Destiny’s lead candidate NTCD-M3 for prevention of recurring Clostridioides difficile (C. difficile) infections.

NTCD-M3 is an oral formulation of a naturally occurring strain of C. difficile that doesn’t contain the genes that produce toxins.

Under the deal, Sebela will gain the North American rights for NTCD-M3 and will lead future clinical development and commercialization activities in North America.

Destiny will receive an upfront payment of $1 million and potential milestone payments of up to $570 million.